5TL9

crystal structure of mPGES-1 bound to inhibitor

5TL9 の概要

• エントリーDOI: 10.2210/pdb5tl9/pdb
• 分子名称: Prostaglandin E synthase, 2-{2-[(1S,2S)-2-{[1-(8-methylquinolin-2-yl)piperidine-4-carbonyl]amino}cyclopentyl]ethyl}benzoic acid, GLUTATHIONE, ... (8 entities in total)
• 機能のキーワード: prostaglandin, enzyme, integral membrane protein, alpha helix, mpges1 - ligand 0, membrane protein, transferase
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 19167.75

構造登録者

Luz, J.G.,Antonysamy, S.,Partridge, K.,Fisher, M. (登録日: 2016-10-10, 公開日: 2017-03-01, 最終更新日: 2025-04-02)

主引用文献

Partridge, K.M.,Antonysamy, S.,Bhattachar, S.N.,Chandrasekhar, S.,Fisher, M.J.,Fretland, A.,Gooding, K.,Harvey, A.,Hughes, N.E.,Kuklish, S.L.,Luz, J.G.,Manninen, P.R.,McGee, J.E.,Mudra, D.R.,Navarro, A.,Norman, B.H.,Quimby, S.J.,Schiffler, M.A.,Sloan, A.V.,Warshawsky, A.M.,Weller, J.M.,York, J.S.,Yu, X.P.
Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.
Bioorg. Med. Chem. Lett., 27:1478-1483, 2017

PubMed Abstract: We describe a novel class of acidic mPGES-1 inhibitors with nanomolar enzymatic and human whole blood (HWB) potency. Rational design in conjunction with structure-based design led initially to the identification of anthranilic acid 5, an mPGES-1 inhibitor with micromolar HWB potency. Structural modifications of 5 improved HWB potency by over 1000×, reduced CYP2C9 single point inhibition, and improved rat clearance, which led to the selection of [(cyclopentyl)ethyl]benzoic acid compound 16 for clinical studies. Compound 16 showed an IC of 24nM for inhibition of PGE formation in vitro in LPS-stimulated HWB. A single oral dose resulted in plasma concentrations of 16 that exceeded its HWB IC in both rat (5mg/kg) and dog (3mg/kg) for over twelve hours.

PubMed: 28190634
DOI: 10.1016/j.bmcl.2016.11.011

実験手法

X-RAY DIFFRACTION (1.2 Å)